Legend Biotech Reveals 5-Year Survival Data for CARVYKTI® at ASCO 2025

The latest announcement is out from Legend Biotech ( (LEGN) ).

On June 3, 2025, Legend Biotech announced groundbreaking five-year survival data from the CARTITUDE-1 study at the ASCO Annual Meeting, revealing that one-third of patients with relapsed/refractory multiple myeloma remained progression-free after a single infusion of CARVYKTI®. This data suggests a potential paradigm shift in treatment expectations for these patients. Additionally, preliminary results from Phase 1 studies in solid tumors, including lung and gastric cancers, showed promising safety and efficacy, highlighting the potential of Legend Biotech’s next-generation cell therapies.

The most recent analyst rating on (LEGN) stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on Legend Biotech stock, see the LEGN Stock Forecast page.

Spark’s Take on LEGN Stock

According to Spark, TipRanks’ AI Analyst, LEGN is a Neutral.

Legend Biotech’s overall score reflects strong revenue growth and strategic plans for profitability, but is tempered by current financial losses and negative technical indicators. The positive outlook from the earnings call adds optimism, but cash flow issues and valuation concerns weigh down the score.

To see Spark’s full report on LEGN stock, click here.

More about Legend Biotech

Legend Biotech Corporation is a global leader in cell therapy, focusing on developing innovative treatments for cancer. The company is known for its CAR T-cell therapies, particularly targeting multiple myeloma and solid tumors, with a market focus on providing advanced therapeutic solutions for heavily pretreated patients.

Average Trading Volume: 1,489,812

Technical Sentiment Signal: Sell

Current Market Cap: $5.4B

For a thorough assessment of LEGN stock, go to TipRanks’ Stock Analysis page.